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Summary 
 
 Disease causing Leptospira can be placed 
in one of two broad categories for common 
domesticated mammals: They are either host-
adapted or incidental strains. The four inciden-
tal serovars of Leptospira that are pathogenic 
to cattle are: L. pomona, L. grippotyphosa, L. 
canicola and L. icterhemmorhagiae. They are 
transmitted to cattle from other carrier animals 
that act as hosts for these strains. The strains 
are found in chronically infected rats, dogs, 
deer, or even pigs and are transmitted to cattle 
though urine-contaminated water. When the 
incidental strains of Leptospira are introduced 
into an unvaccinated, susceptible herd of cat-
tle, they commonly cause an outbreak of abor-
tions in the mid- to late-term pregnant cows. 
Commercial five-way Leptospiral vaccines are 
effective in preventing the abortion storms 
associated with the incidental strains of Lepto-
spira, but ineffective to the most common se-
rovar found in cattle (hardjo-bovis). Pfizer 
Animal Health recently received USDA ap-
proval to market the first effective L. hardjo 
vaccine, known as Spirovac®, in the United 
States. 
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Background 
 
 The host-adapted strain for cattle in the 
United States is Leptospira borgpetersenii se-
rovar hardjo (Type: hardjo-bovis), commonly 
referred to as L. hardjo. The primary source of 
L. hardjo-bovis for uninfected cattle is the 
urine of chronically infected cattle. Once cat-
tle are infected, they may shed the organism in 
the urine for weeks or years. The primary 
manifestation of hardjo-bovis in cattle is a 
mild disease characterized primarily by low 
conception rates, but may cause embryonic 
deaths, abortions, and stillbirths.  
 
 The first report indicating that the current 
five-way leptospiral vaccines were ineffective 
in providing protection against infections from 
L. hardjo was published by Bolin in 1989. 
Bolin had three groups of experimental ani-
mals: 1) an unvaccinated control group, 2) a 
group of cows that was vaccinated once, and 
3) a group of cows that was vaccinated twice. 
All three experimental groups of cattle were 
bred after control or treatment vaccinations, 
and at midgestation they were experimentally 
challenged with a virulent strain of L. hardjo. 
All control cows and 13 of 16 vaccinated 
cows became infected and shed L. hardjo in 
the urine. The percentage of urine specimens 
that contained Leptospira organisms was re-
duced in the experimental groups of vacci-
nated cattle compared to controls (79% vs. 
11%, respectively). The calves from these 
cows were sacrificed after birth and Lepto-
spira organisms were identified in the kidneys 
of 17 of 19 of the calves from control and 
vaccinated cows. The authors concluded the 
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current five-way vaccines failed to prevent 
renal-shedding of L. hardjo in the urine of the 
cows and failed to prevent fetal infection with 
the organism in the fetal kidneys. 
 
 In a later study Bolin demonstrated that 
vaccination with L. hardjo vaccine altered the 
serological response to the disease so the titers 
of L. hardjo-challenged cattle that were vacci-
nated were no different than that of non-
challenged vaccinated cattle. Nonvaccinated 
cattle that were challenged with L. hardjo de-
veloped titers that were diagnostic of L. 
hardjo infections. The conclusion was that the 
vaccine not only provided little to no protec-
tion to cattle for the prevention of renal infec-
tion of dams or fetal infection, but it made se-
rological diagnosis of L. hardjo, the traditional 
method for diagnosing the disease, impossible. 
The only positive factor about the existing 
vaccines with respect to L. hardjo is that they 
may reduce the duration of renal shedding in 
cows. It was not until state-supported diagnos-
tic laboratories began to offer fluorescent an-
tibody and PCR tests for identification of the 
organism in cattle urine in the late 1990s that 
disease diagnosis became practical. 
 
Recent Findings 
 
 A recent survey was conducted to deter-
mine the incidence of L. hardjo infections in 
U.S. dairy herds. Eleven herds were selected 
in each of four regions of the country: South-
east, Midwest, Northwest, and West. Of the 44 
herds in the survey, 57% were infected with L. 
hardjo, the most common form of Leptospira 
in dairy cattle. Within herds that were positive 
of L. hardjo, it is estimated that 30% of the 
cows were infected. 
 
 Low conception rates in dairy herds can be 
caused by numerous factors. When a dairy 
herd experiences low conception rates, L. 
hardjo should be considered in the differential 
diagnosis. Urine samples should be collected 
and sent to a diagnostic laboratory familiar 
with performing either the fluorescent anti-
body or PCR tests that allow identification of 
the organism in urine. Another characteristic 
observed in herds with endemic L. hardjo is a 
lower pregnancy rate in first-lactation cows in 
the majority of estrous cycles after the end of 
the voluntary waiting period when compared 
to second or greater lactating cows. Normally 
first lactation cows are more fertile and have 
greater pregnancy rates than older cows.  
 
 Pfizer Animal Health recently received 
USDA approval to market in the United States 
the first effective L. hardjo vaccine, known as 
Spirovac®. The vaccine has been available to 
dairy producers in other areas of the world for 
several years. Immunizing dairy animals con-
sists of initial administration of two doses of 
vaccine 4 to 6 weeks apart, followed by an-
nual vaccination. Some producers have chosen 
to vaccinate cows as they go through the dry 
period, whereas others have chosen to vacci-
nate the entire herd at one time. Initial reports 
from herds that have been diagnosed with L. 
hardjo and have been vaccinated look promis-
ing. 
 
